The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma
Oncology · 2024
DOI: 10.1159/000541372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Takanori Mukozu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo…. Hauptthemen laut MEDLINE: Interleukin-6, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Introduction
In atezolizumab plus bevacizumab (Atezo/Bev) combination treatment, both drugs act on the immune system. Previously, we reported that immunological changes after Atezo/Bev administration for unresectable hepatocellular carcinoma (uHCC) revealed significant alterations in interleukin (IL)-6, soluble IL-2 receptor, tumor necrosis factor-alpha, and programmed cell death-1 levels. Among these variable factors, serum levels of IL-6 can be easily measured on a commercial basis. Therefore, this study aimed to investigate the utility of serum IL-6 as a predictor of tumor response to Atezo/Bev treatment for uHCC.
Method
The study included 44 patients with HCC treated with Atezo/Bev. Blood samples were collected before and 3 weeks after treatment, and tumor response was assessed using contrast-enhanced computed tomography 6 weeks after treatment.
Results
Significant changes in serum IL-6 levels were observed in patients treated with Atezo/Bev as first-line therapy but not in those treated with it as second-line or later-line therapy. In patients treated with Atezo/Bev as first-line therapy, serum IL-6 levels increased significantly after treatment in patients with a complete or partial response but not in patients with stable or progressive disease. Furthermore, compared to other tumor markers such as alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein, and des-gamma-carboxyprothrombin, serum IL-6 levels exhibited the highest sensitivity in predicting tumor response during the treatment period.
Conclusion
In patients with uHCC treated with Atezo/Bev, serum IL-6 levels could serve as a potential predictor of tumor response. Elevated levels after treatment may indicate a favorable tumor response and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
- Department of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
Zitieren
APA
Mukozu, T., Nagai, H., Nagumo, H., Mohri, K., Yoshimine, N., Kobayashi, K., Ogino, Y., Matsui, T., Daido, Y., Wakui, N., Momiyama, K., Higai, K., Matsuda, T., & Igarashi, Y. (2024). The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000541372
Vancouver
Mukozu T, Nagai H, Nagumo H, Mohri K, Yoshimine N, Kobayashi K, et al. The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma. Oncology. 2024. doi:10.1159/000541372
BibTeX
@article{Mukozu2024,
author = {Mukozu, Takanori and Nagai, Hidenari and Nagumo, Hideki and Mohri, Kunihide and Yoshimine, Naoyuki and Kobayashi, Kojiro and Ogino, Yu and Matsui, Teppei and Daido, Yasuko and Wakui, Noritaka and Momiyama, Koichi and Higai, Koji and Matsuda, Takahisa and Igarashi, Yoshinori},
title = {The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma},
journal = {Oncology},
year = {2024},
doi = {10.1159/000541372}
}
EUVIMED